Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections-Reference-Cited by-同舟云学术

Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Morata L.¹,Cobo J.²,Fernández-Sampedro M.³,Guisado Vasco P.⁴,Ruano E.⁵,Lora-Tamayo J.⁶,Sánchez Somolinos M.⁷,González Ruano P.⁸,Rico Nieto A.⁹^ORCID,Arnaiz A.¹⁰,Estébanez Muñoz M.¹¹,Jiménez-Mejías M. E.¹²,Lozano Serrano A. B.¹³,Múñez E.¹⁴,Rodriguez-Pardo D.¹⁵,Argelich R.¹⁶,Arroyo A.¹⁷,Barbero J. M.¹⁸,Cuadra F.¹⁹,Del Arco A.²⁰,del Toro M. D.²¹²²,Guio L.²³,Jimenez-Beatty D.²⁴,Lois N.²⁵,Martin O.²⁶,Martínez Alvarez R. M.²⁷,Martinez-Marcos F. J.²⁸,Porras L.²⁹,Ramírez M.³⁰,Vergas García J.³¹,Soriano A.¹

Affiliation:

1. Department of Infectious Diseases, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

2. Department of Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain

3. Infectious Diseases Unit, Department of Medicine, Hospital Universitario Marques de Valdecilla, Santander, Spain

4. Department of Infectious Diseases, Complejo Hospitalario Quirón Ruber Juan Bravo, Madrid, Spain

5. Department of Infectious Diseases, Hospital Universitario de Getafe, Madrid, Spain

6. Department of Internal Medicine. Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain

7. Department of Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

8. Department of Infectious Diseases, Hospital Infanta Sofía, Madrid, Spain

9. Department of Infectious Diseases and Clinical Microbiology, Hospital Universitario La Paz, Madrid, Spain

10. Clínica Mompía, Santander, Spain

11. Unit of Infectious Diseases, Internal Medicine, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain

12. Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University of Seville/CSIC/University Hospital Virgen del Rocio, Seville, Spain

13. Tropical Diseases Unit, Hospital de Poniente, Almería, Spain

14. Department of Internal Medicine and Infectious Diseases, Hospital Universitario Puerta de Hierro, Madrid, Spain

15. Department of Infectious Diseases, Hospital Universitari Vall d’Hebron, Barcelona, Spain

16. Department of Internal Medicine, Centro Médico Téknon, Barcelona, Spain

17. Infectious Diseases Unit, Complejo Hospitalario de Jaén, Jaén, Spain

18. Department of Internal Medicine, Hospital Príncipe de Asturias, Universidad de Alcalá, Madrid, Spain

19. Unit of Infectious Diseases, Department of Internal Medicine, Complejo Hospitalario Universitario de Toledo, Toledo, Spain

20. Department of Internal Medicine, Hospital Costa del Sol, Marbella, Spain

21. Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena, Seville, Spain

22. Institute of Biomedicine of Seville, University of Seville, Seville, Spain

23. Unit of Infectious Diseases, Hospital Universitario Cruces, Bilbao, Spain

24. Department of Internal Medicine, Hospital Vithas Nuestra Señora de Fátima, Pontevedra, Spain

25. Department of Internal Medicine, Hospital Universitario Severo Ochoa, Madrid, Spain

26. Department of Internal Medicine, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain

27. Unit of Infectious Diseases, Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain

28. Unit of Infectious Diseases, Hospital Juan Ramón Jiménez, Huelva, Spain

29. Department of Internal Medicine, General Universitario Ciudad Real, Ciudad Real, Spain

30. Department of Internal Medicine, Hospital Universitario Arnau de Vilanova, Lleida, Spain

31. Department of Internal Medicine and Infectious Diseases, Hospital San Carlos, Madrid, Spain

Abstract

Dalbavancin is a lipoglycopeptide with potent activity against Gram-positive microorganisms, a long half-life, a favorable safety profile, and a high concentration in bone, which makes it an interesting alternative for treatment of osteoarticular infections. We performed a multicentric retrospective study of all patients with an osteoarticular infection (septic arthritis, spondylodiscitis, osteomyelitis, or orthopedic implant-related infection) treated with at least one dose of dalbavancin between 2016 and 2017 in 30 institutions in Spain.

Funder

Agencia de Gestio d'Ajust Universitaris I de Recerca

Red Española de Investigación en Patología Infecciosa

MINECO | Instituto de Salud Carlos III

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02280-18

Reference27 articles.

1. Adaptive processes ofStaphylococcus aureusisolates during the progression from acute to chronic bone and joint infections in patients